Intestinal Blautia Is Associated with Reduced Death from Graft-versus-Host Disease

Biology of Blood and Marrow Transplantation

Volumn 21, Issue 8, 2015, Pages 1373-1383

  Jenq, Robert R ^a,b   Taur, Ying ^a,b   Devlin, Sean M ^a   Ponce, Doris M ^a,b   Goldberg, Jenna D ^a,b   Ahr, Katya F ^a   Littmann, Eric R ^a   Ling, Lilan ^a   Gobourne, Asia C ^a   Miller, Liza C ^a   Docampo, Melissa D ^a   Peled, Jonathan U ^a,b   Arpaia, Nicholas ^a   Cross, Justin R ^a   Peets, Tatanisha K ^a   Lumish, Melissa A ^a   Shono, Yusuke ^a   Dudakov, Jarrod A ^a   Poeck, Hendrik ^a   Hanash, Alan M ^a,b   Barker, Juliet N ^a,b   Perales, Miguel Angel ^a,b   Giralt, Sergio A ^a,b   Pamer, Eric G ^a,b   van den Brink, Marcel R M ^a,b   more..

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Graft versus host disease; Intestinal bacteria

Indexed keywords

AZTREONAM; CALCINEURIN INHIBITOR; CEFEPIME; CEFTAZIDIME; CEFTRIAXONE; CILASTATIN PLUS IMIPENEM; CLAVULANATE PLUS TICARCILLIN; CLAVULANIC ACID; CLINDAMYCIN; COTRIMOXAZOLE; MEROPENEM; METRONIDAZOLE; PIPERACILLIN PLUS TAZOBACTAM; STEROID; TICARCILLIN; UNCLASSIFIED DRUG; VANCOMYCIN;

ADULT; AGED; ALLOGENEIC PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; ANTIBIOTIC PROPHYLAXIS; ARTICLE; BLAUTIA; BONE MARROW TRANSPLANTATION; COHORT ANALYSIS; FECES ANALYSIS; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTESTINE FLORA; MAJOR CLINICAL STUDY; MALE; MORTALITY; NONMYELOABLATIVE CONDITIONING; OVERALL SURVIVAL; TOTAL PARENTERAL NUTRITION; TREATMENT DURATION; VEILLONELLA; BACTERIUM; INTESTINE; METABOLISM; MICROBIOLOGY; RISK FACTOR; SURVIVAL ANALYSIS;

BACTERIA; COHORT STUDIES; FEMALE; GRAFT VS HOST DISEASE; HUMANS; INTESTINES; MALE; RISK FACTORS; SURVIVAL ANALYSIS;

EID: 84937701770     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2015.04.016     Document Type: Article

References (56)

1. Pasquini MC. Current use and outcome of hematopoietic stem cell transplantation. CIBMTR Summary Slides, 2013. Available at: , accessed June 18, 2015. http://www.cibmtr.org.
2. Jones J.M., Wilson R., Bealmear P.M. Mortality and gross pathology of secondary disease in germfree mouse radiation chimeras. Radiat Res 1971, 45:577-588.
3. van Bekkum D.W., Roodenburg J., Heidt P.J., van der Waaij D. Mitigation of secondary disease of allogeneic mouse radiation chimeras by modification of the intestinal microflora. JNatl Cancer Inst 1974, 52:401-404.
4. Storb R., Prentice R.L., Buckner C.D., et al. Graft-versus-host disease and survival in patients with aplastic anemia treated by marrow grafts from HLA-identical siblings. Beneficial effect of a protective environment. NEngl J Med 1983, 308:302-307.
5. Vossen J.M., Heidt P.J., van den Berg H., et al. Prevention of infection and graft-versus-host disease by suppression of intestinal microflora in children treated with allogeneic bone marrow transplantation. Eur JClin Microbiol Infect Dis 1990, 9:14-23.
6. Petersen F.B., Buckner C.D., Clift R.A., et al. Infectious complications in patients undergoing marrow transplantation: a prospective randomized study of the additional effect of decontamination and laminar air flow isolation among patients receiving prophylactic systemic antibiotics. Scand J Infect Dis 1987, 19:559-567.
7. Passweg J.R., Rowlings P.A., Atkinson K.A., et al. Influence of protective isolation on outcome of allogeneic bone marrow transplantation for leukemia. Bone Marrow Transplant 1998, 21:1231-1238.
8. Russell J.A., Chaudhry A., Booth K., et al. Early outcomes after allogeneic stem cell transplantation for leukemia and myelodysplasia without protective isolation: a 10-year experience. Biol Blood Marrow Transplant 2000, 6:109-114.
9. Martin P.J., McDonald G.B., Sanders J.E., et al. Increasingly frequent diagnosis of acute gastrointestinal graft-versus-host disease after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2004, 10:320-327.
10. Beelen D.W., Elmaagacli A., Muller K.D., et al. Influence of intestinal bacterial decontamination using metronidazole and ciprofloxacin or ciprofloxacin alone on the development of acute graft-versus-host disease after marrow transplantation in patients with hematologic malignancies: final results and long-term follow-up of an open-label prospective randomized trial. Blood 1999, 93:3267-3275.
11. Atarashi K., Tanoue T., Oshima K., et al. Treg induction by a rationally selected mixture of Clostridia strains from the human microbiota. Nature 2013, 500:232-236.
12. Taur Y., Jenq R.R., Perales M.A., et al. The effects of intestinal tract bacterial diversity on mortality following allogeneic hematopoietic stem cell transplantation. Blood 2014, 124:1174-1182.
13. Jakubowski A.A., Small T.N., Kernan N.A., et al. Tcell-depleted unrelated donor stem cell transplantation provides favorable disease-free survival for adults with hematologic malignancies. Biol Blood Marrow Transplant 2011, 17:1335-1342.
14. Goldberg J.D., Linker A., Kuk D., et al. Tcell-depleted stem cell transplantation for adults with high-risk acute lymphoblastic leukemia: long-term survival for patients in first complete remission with a decreased risk of graft-versus-host disease. Biol Blood Marrow Transplant 2013, 19:208-213.
15. Theurich S., Fischmann H., Shimabukuro-Vornhagen A., et al. Polyclonal anti-thymocyte globulins for the prophylaxis of graft-versus-host disease after allogeneic stem cell or bone marrow transplantation in adults. Cochrane Database System Rev 2012, CD009159.
16. Taur Y., Xavier J.B., Lipuma L., et al. Intestinal domination and the risk of bacteremia in patients undergoing allogeneic hematopoietic stem cell transplantation. Clin Infect Dis 2012, 55:905-914.
17. Rowlings P.A., Przepiorka D., Klein J.P., et al. IBMTR Severity Index for grading acute graft-versus-host disease: retrospective comparison with Glucksberg grade. Br J Haematol 1997, 97:855-864.
18. Vigorito A.C., Campregher P.V., Storer B.E., et al. Evaluation of NIH consensus criteria for classification of late acute and chronic GVHD. Blood 2009, 114:702-708.
19. Ponce D.M., Gonzales A., Lubin M., et al. Graft-versus-host disease after double-unit cord blood transplantation has unique features and an association with engrafting unit-to-recipient HLA match. Biol Blood Marrow Transplant 2013, 19:904-911.
20. Copelan E., Casper J.T., Carter S.L., et al. Ascheme for defining cause of death and its application in the T cell depletion trial. Biol Blood Marrow Transplant 2007, 13:1469-1476.
21. Transplantation ASfBaM. ASBMT RFI 2014: Disease classifications corresponding to CIBMTR classifications2014. , accessed November 1, 2014. http://www.asbmt.org/?RFIForms.
22. Bacigalupo A., Ballen K., Rizzo D., et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant 2009, 15:1628-1633.
23. Solomkin J.S., Mazuski J.E., Bradley J.S., et al. Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Societyof America. Clin Infect Dis 2010, 50:133-164.
24. Jaffe D., Jakubowski A., Sepkowitz K., et al. Prevention of peritransplantation viridans streptococcal bacteremia with early vancomycin administration: a single-center observational cohort study. Clin Infect Dis 2004, 39:162516-162532.
25. Turnbaugh P.J., Hamady M., Yatsunenko T., et al. Acore gut microbiome in obese and lean twins. Nature 2009, 457:480-484.
26. Schloss P.D., Westcott S.L., Ryabin T., et al. Introducing mothur: open-source, platform-independent, community-supported software for describing and comparing microbial communities. Appl Environ Microbiol 2009, 75:7537-7541.
27. Schloss P.D., Gevers D., Westcott S.L. Reducing the effects of PCR amplification and sequencing artifacts on 16S rRNA-based studies. PLoS One 2011, 6:e27310.
28. Wang Q., Garrity G.M., Tiedje J.M., Cole J.R. Naive Bayesian classifier for rapid assignment of rRNA sequences into the new bacterial taxonomy. Appl Environ Microbiol 2007, 73:5261-5267.
29. DeSantis T.Z., Hugenholtz P., Larsen N., et al. Greengenes, a chimera-checked 16S rRNA gene database and workbench compatible with ARB. Appl Environ Microbiol 2006, 72:5069-5072.
30. Magurran A.E. Measuring biological diversity 2004, Blackwell, Malden, MA.
31. Shannon C.E. The mathematical theory of communication 1963. MD Comput Comput Med Pract 1997, 14:306-317.
32. Caporaso J.G., Kuczynski J., Stombaugh J., et al. QIIME allows analysis of high-throughput community sequencing data. Nat Methods 2010, 7:335-336.
33. Segata N., Izard J., Waldron L., et al. Metagenomic biomarker discovery and explanation. Genome Biol 2011, 12:R60.
34. Clifford R.J., Milillo M., Prestwood J., et al. Detection of bacterial 16S rRNA and identification of four clinically important bacteria by real-time PCR. PLoS One 2012, 7:e48558.
35. Saha P., Heagerty P.J. Time-dependent predictive accuracy in the presence of competing risks. Biometrics 2010, 66:999-1011.
36. Moellering R.C. Pharmacokinetics of vancomycin. JAntimicrob Chemother 1984, 14(Suppl D):43-52.
37. Ahmad T., Fiuzat M., Neely B., et al. Biomarkers of myocardial stress and fibrosis as predictors of mode of death in patients with chronic heart failure. JACC Heart Failure 2014, 2:260-268.
38. Liu C., Finegold S.M., Song Y., Lawson P.A. Reclassification of Clostridium coccoides, Ruminococcus hansenii, Ruminococcus hydrogenotrophicus, Ruminococcus luti, Ruminococcus productus and Ruminococcus schinkii as Blautia coccoides gen. nov., comb. nov., Blautia hansenii comb. nov., Blautia hydrogenotrophica comb. nov., Blautia luti comb. nov., Blautia producta comb. nov., Blautia schinkii comb. nov. and description of Blautia wexlerae sp. nov., isolated from human faeces. Int J Syst Evol Microbiol 2008, 58:1896-1902.
39. Park S.K., Kim M.S., Bae J.W. Blautia faecis sp. nov., isolated from human faeces. Int J Syst Evol Microbiol 2013, 63:599-603.
40. Holler E., Butzhammer P., Schmid K., et al. Metagenomic analysis of the stool microbiome in patients receiving allogeneic stem cell transplantation: loss of diversity is associated with use of systemic antibiotics and more pronounced in gastrointestinal graft-versus-host disease. Biol Blood Marrow Transplant 2014, 20:640-645.
41. Gerbitz A., Schultz M., Wilke A., et al. Probiotic effects on experimental graft-versus-host disease: let them eat yogurt. Blood 2004, 103:4365-4367.
42. Jenq R.R., Ubeda C., Taur Y., et al. Regulation of intestinal inflammation by microbiota following allogeneic bone marrow transplantation. JExp Med 2012, 209:903-911.
43. Mazmanian S.K., Round J.L., Kasper D.L. Amicrobial symbiosis factor prevents intestinal inflammatory disease. Nature 2008, 453:620-625.
44. Weisdorf D., Hakke R., Blazar B., et al. Risk factors for acute graft-versus-host disease in histocompatible donor bone marrow transplantation. Transplantation 1991, 51:1197-1203.
45. Jagasia M., Arora M., Flowers M.E., et al. Risk factors for acute GVHD and survival after hematopoietic cell transplantation. Blood 2012, 119:296-307.
46. Hahn T., McCarthy P.L., Zhang M.J., et al. Risk factors for acute graft-versus-host disease after human leukocyte antigen-identical sibling transplants for adults with leukemia. JClin Oncol 2008, 26:5728-5734.
47. MacMillan M.L., DeFor T.E., Weisdorf D.J. What predicts high risk acute graft-versus-host disease (GVHD) at onset? Identification of those at highest risk by a novel acute GVHD risk score. Br J Haematol 2012, 157:732-741.
48. Vander Lugt M.T., Braun T.M., Hanash S., et al. ST2 as a marker for risk of therapy-resistant graft-versus-host disease and death. NEngl J Med 2013, 369:529-539.
49. Chen W., Liu F., Ling Z., et al. Human intestinal lumen and mucosa-associated microbiota in patients with colorectal cancer. PLoS One 2012, 7:e39743.
50. Bajaj J.S., Hylemon P.B., Ridlon J.M., et al. Colonic mucosal microbiome differs from stool microbiome in cirrhosis and hepatic encephalopathy and is linked to cognition and inflammation. Am J Physiol Gastrointest Liver Physiol 2012, 303:G675-G685.
51. Malard F., Szydlo R.M., Brissot E., et al. Impact of cyclosporine-A concentration on the incidence of severe acute graft-versus-host disease after allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2010, 16:28-34.
52. Barrell C., Dietzen D., Jin Z., et al. Reduced-intensity conditioning allogeneic stem cell transplantation in pediatric patients and subsequent supportive care. Oncol Nurs Forum 2012, 39:E451-E458.
53. Russell W.R., Gratz S.W., Duncan S.H., et al. High-protein, reduced-carbohydrate weight-loss diets promote metabolite profiles likely to be detrimental to colonic health. Am J Clin Nutr 2011, 93:1062-1072.
54. David L.A., Maurice C.F., Carmody R.N., et al. Diet rapidly and reproducibly alters the human gut microbiome. Nature 2014, 505:559-563.
55. Gallo R.L., Hooper L.V. Epithelial antimicrobial defence of the skin and intestine. Nat Rev Immunol 2012, 12:503-516.
56. Seguy D., Berthon C., Micol J.B., et al. Enteral feeding and early outcomes of patients undergoing allogeneic stem cell transplantation following myeloablative conditioning. Transplantation 2006, 82:835-839.